Drug Trial Radar · NCT06071624
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
30
Planned (sponsor's estimate)
Start
Feb 21, 2024
Primary completion
Dec 2028
Study completion Dec 2043
Sponsor
- Lead sponsor
- Huda SalmanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- iCell Gene Therapeutics; The Leukemia and Lymphoma Society
- First posted
- Oct 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory CMML. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells.
Conditions
- Chronic Myelomonocytic Leukemia
Interventions
CD4CARBiological
CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose finding: Maximum tolerated dose (MTD) is defined as one dose level lower than the dose limiting toxicity (DLT) of the CD4CAR in CMMLTime frame: Day 0 through Day 28 post-infusion
- The efficacy of treatment with CD4CAR and description of CMML response to CD4CARTime frame: Day 28 through 6 months post-infusion
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida 33136
Miami, Florida
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
Albert Einstein Health Network
The Bronx, New York
The University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.